Navigation Links
New !! “Designer” Gene Theray

Gene therapy works by inserting modified genes to treat an illness or condition into a virus that has been made harmless to humans.
But injecting these gene-carrying viruses into a person’s bloodstream has been a problem, because most of the virus ends up in the liver, which naturally isolates foreign bodies and washes them out of the blood.// That makes it difficult to deliver enough of the new genes to the part of the body that needs assistance.

New research shows a form of gene therapy capable of entering the bloodstream and traveling directly to the part of the body that needs treatment may be on the horizon.

Scientists from the University of Glasgow in Scotland have now developed a “designer” gene therapy that bypasses the liver. The new therapy uses an adeno-associated virus, or AAV, which has been redesigned to avoid capture by the liver long enough to get to the part of the body needing the new genes.They’ve tested two forms of the virus in the laboratory and in mice, using it to deliver new genes to vascular endothelial cells, which are the cells that line the inside of blood vessels. These cells play a major role in many cardiovascular abnormalities. Researchers redesigned the virus by modifying two small proteins called peptides.

More work will be needed before the therapy can be tried in humans, but researchers believe these findings hold promise for the future.
'"/>




Page: 1

Related medicine news :

1. Low Birth Weight infants could have Problems in the Future
2. New Virus : A Threat In the Future?
3. Will Your Baby Grow Up To Be A Future Einstein ?
4. Genetic Pills A Future Thought
5. Prediction Of Disease In The Future Questioned
6. Asthmatics May Be At Risk for Lung Disease In The Future
7. Eyes,The Window To The Future
8. Use Of Sunscreen In Childhood And Prevents Future Skin Cancer
9. Childrens Waistlines A Predictor Of Future Heart Disease
10. Recent Study On Rats May Lead To Future Robotics
11. Predicting The Risk Of Breast Cancer In The Future
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... Plano, TX (PRWEB) , ... April 26, 2017 ... ... to confer the distinction of Customer Excellence upon National Registry of Emergency ... , “Customer Engagement drives Financial Performance,” said Dr. Jan G. West, Ph.D. ...
(Date:4/26/2017)... ... , ... RawTrition now brings you BioEnergy which is a powder capsule whole ... , RawTrition is taking nutrients to the next level! The superfoods in RawTrition's ... form (unlike the synthetically made options that are on the market). , Founder of ...
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 product ... for education and business. , Mirroring360 Pro enables educators, business professionals and individuals ...
(Date:4/25/2017)... Amherst, NY (PRWEB) , ... April 25, 2017 , ... ... much stress at work can also decrease overall productivity and performance in the workplace. ... their employees. , During the last few weeks of April, Clearview Resolution Services will ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Urology, Uro/Gyn and Gynecology markets with innovative and ... joined the Company as Senior Vice President, Marketing ... Mr. Keswani will report directly to Darin ... organization is delighted that Ash has joined the ...
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: